comparemela.com

Latest Breaking News On - Belzutifan - Page 1 : comparemela.com

Dr Gopal on Treatment Selection in Second-Line R/R mUC

Nikhil A. Gopal, MD, discusses treatment selection in second-line relapsed/ refractory metastatic urothelial cancer.

Nikhila gopalDepartment of urologyUniversity of tennessee health science centerCollege of medicineTennessee health science center

Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Wenxin vincent xuDana farber cancer instituteHarvard medical schoolMetastatic renal cell carcinoma

Dr Gopal on the Advantages and Potential Benefit of Belzutifan in RCC

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.

Nikhila gopalCollege of medicineDepartment of urologyUniversity of tennessee health science centerTennessee health science center

Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Thomas powlesBarts cancer centerQueen mary university of londonFunctional assessmentQueen mary universityQuality of life outcomesPatients with advanced renal cell carcinomaLitespark 005 trial

FDA Approves Kidney Cancer Therapy After Dana-Farber-Led Research Shows Improved Outcomes for Patients with Advanced Disease

Belzutifan, a HIF-2α inhibitor, has been approved by the FDA for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and antiangiogenic therapies.

Tonik choueiriMerck sharp dohmeGenitourinary cancer at dana farber instituteLank centerEuropean society of medical oncologyDrug administrationGenitourinary cancerDana farber cancerEuropean societyMedical oncologyVon hippel landauNobel prizeMerck sharpHif 2α inhibitorFda approvalDana farber cancer institute

vimarsana © 2020. All Rights Reserved.